[68Ga]CBP8 for Lung Diseases, Interstitial

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Massachusetts General Hospital, Boston, MA
Lung Diseases, Interstitial+2 More
[68Ga]CBP8 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study if a new 68Ga-labeled peptide can help detect early stages of interstitial lung disease. The FDA has approved [68Ga]CBP8 to treat interstitial lung diseases. This is the first time the drug has been approved to treat this condition.

Eligible Conditions

  • Lung Diseases, Interstitial

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Lung Diseases, Interstitial

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 24 months

24 months
Degree of uptake of [68Ga]CBP8
Peak enhancement of MRI contrast in the lungs
Rate of MRI contrast arrival, Kwashin, in the lungs
Rate of MRI contrast clearance, Kwashout, in the lungs

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Lung Diseases, Interstitial

Trial Design

2 Treatment Groups

Subjects with interstitial lung abnormalities (ILAs) or interstitial lung diseas...
1 of 2
First degree relatives of a family member with pulmonary fibrosis
1 of 2
Experimental Treatment

30 Total Participants · 2 Treatment Groups

Primary Treatment: [68Ga]CBP8 · No Placebo Group · Phase 2

Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD)Experimental Group · 2 Interventions: [68Ga]CBP8, Dotarem · Intervention Types: Drug, Drug
First degree relatives of a family member with pulmonary fibrosisExperimental Group · 2 Interventions: [68Ga]CBP8, Dotarem · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dotarem
2017
Completed Phase 4
~1790

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 24 months
Closest Location: Massachusetts General Hospital · Boston, MA
Photo of Massachusetts General Hospital 1Photo of Massachusetts General Hospital 2Photo of Massachusetts General Hospital 3
1993First Recorded Clinical Trial
4 TrialsResearching Lung Diseases, Interstitial
2440 CompletedClinical Trials

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,661 Previous Clinical Trials
30,828,222 Total Patients Enrolled
Boehringer IngelheimIndustry Sponsor
2,373 Previous Clinical Trials
9,768,317 Total Patients Enrolled
27 Trials studying Lung Diseases, Interstitial
13,312 Patients Enrolled for Lung Diseases, Interstitial

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a first degree relative of a family member with pulmonary fibrosis.
You have a first degree relative with pulmonary fibrosis.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.